Design Therapeutics, Inc. (DSGN)
Company Description
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions.
The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs.
It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy.
Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Mar 26, 2021 |
| Industry | Biotechnology |
| Sector | Health Care |
| Employees | 44 |
Contact Details
Address: 6005 Hidden Valley Road Carlsbad, CA 92011 United States | |
| Phone | 858 293 4900 |
| Website | designtx.com |
Stock Details
| Ticker Symbol | DSGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| IPO Price | $20.00 |
| CIK Code | 1807120 |
Key Executives
| Name | Position |
|---|---|
| Dr. João Siffert M.D. | President, Chief Executive Officer and Director |
| Dr. Sean Jeffries Ph.D. | Chief Operating Officer |
| Dr. Aseem Z. Ansari Ph.D. | Co-Founder and Scientific Advisor |
| Julie D. Burgess CPA | Chief Accounting Officer |
| Dr. Elizabeth Gordon Ph.D. | Senior Vice President of Regulatory Affairs |
| Dr. Jae B. Kim FACC, M.D. | Chief Medical Officer |
| Dawn Giangiulio | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 10, 2022 | EFFECT | Notice of Effectiveness |
| May 9, 2022 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
| May 9, 2022 | 8-K | Current report |
| Apr 27, 2022 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 27, 2022 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 27, 2022 | DEF 14A | Other definitive proxy statements |
| Mar 31, 2022 | SC 13D | General statement of acquisition of beneficial ownership |
| Mar 22, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Mar 22, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Mar 22, 2022 | 8-K | Current report |
| View All SEC Filings | ||